Insulin pump malfunction settlement amounts depend on the type of device failure, severity of the resulting hypoglycemia or ketoacidosis, FDA recall classification, and whether the manufacturer knew of the defect before the injury occurred.
This site is operated by Mustafa Bilgic, an individual based in Adiyaman, Turkiye. The operator is NOT a licensed attorney, NOT a law firm, and does NOT provide legal advice. This page is an informational legal research reference compiled from public FDA records, agency guidance, and legal-education sources. Always verify current law with the official state publisher and consult a licensed attorney in the relevant state.
Address: Malazgirt No: 225, 02000 Adiyaman, Turkiye
Email: [email protected]
This page does not publish fake verdicts, invented settlement averages, or testimonials. Dollar examples are hypothetical worksheets only. Public sources are linked in the cited sources section.
An insulin pump malfunction settlement amount in 2026 can range widely depending on the nature of the device failure and the resulting medical harm. Insulin pumps are Class II or Class III medical devices regulated by the FDA, and they deliver continuous subcutaneous insulin to approximately 1.5 million Americans with diabetes, according to published endocrinology literature. When these devices malfunction, the consequences can be life-threatening. Over-delivery of insulin causes severe hypoglycemia, which can produce seizures, brain damage, coma, and death. Under-delivery causes diabetic ketoacidosis (DKA), which can lead to organ failure and death if untreated.
The FDA has issued multiple Class I recalls -- the most serious category, indicating a reasonable probability of serious adverse health consequences or death -- for insulin pump systems. Medtronic's MiniMed 600 and 700 series pumps have been subject to several recalls addressing issues including potential over-delivery of insulin, retainer ring failures in reservoir connections, and software errors affecting dose calculations. These recalls generate strong evidence for product liability claims because Class I classification means the FDA itself determined the defect could cause serious harm or death.
| Defect type | Medical consequence | Key liability factor | Relative claim value |
|---|---|---|---|
| Over-delivery (excess insulin) | Severe hypoglycemia, seizure, brain injury, death | Manufacturing or software defect; recall evidence | High to catastrophic |
| Under-delivery (insufficient insulin) | DKA, organ damage, hospitalization | Infusion set failure, occlusion alarm failure | Moderate to high |
| Software/algorithm error | Incorrect bolus calculation, wrong basal rate | Design defect; closed-loop system errors | Moderate to high |
| Battery or alarm failure | Undetected loss of insulin delivery | Failure to warn; no backup alarm | Moderate |
| Infusion set disconnection | Unnoticed insulin interruption, DKA | Design defect in connector; inadequate training | Moderate |
| Cybersecurity vulnerability | Unauthorized dose alteration | FDA safety communication; design defect | Case-specific |
Insulin pump injury claims typically proceed under three product liability theories. A manufacturing defect claim alleges the specific pump deviated from the intended design during production. A design defect claim alleges the pump's design was unreasonably dangerous even when manufactured correctly -- for example, a closed-loop algorithm that miscalculates insulin needs. A failure to warn claim alleges the manufacturer did not adequately warn about known risks, such as potential over-delivery in certain usage conditions.
Most insulin pumps reach the market through the FDA's 510(k) clearance pathway, not the more rigorous Pre-Market Approval (PMA) process. This distinction matters legally because PMA-approved devices receive stronger federal preemption protection under the Supreme Court's decision in Riegel v. Medtronic (2008). Since most insulin pumps are 510(k)-cleared, state product liability claims generally survive federal preemption challenges, giving plaintiffs broader access to state courts.
The manufacturer of the pump hardware bears primary product liability exposure. However, additional defendants may include the software developer if the algorithm was created by a separate entity, the infusion set manufacturer, the distributor or pharmacy, and in some cases the prescribing endocrinologist if the device was contraindicated for the patient's condition. In closed-loop or hybrid closed-loop systems, the continuous glucose monitor (CGM) manufacturer may also share liability if sensor inaccuracy caused the pump to deliver an incorrect dose.
A patient's insulin pump over-delivers insulin during sleep due to a retainer ring failure. The patient suffers a severe hypoglycemic episode resulting in a seizure and brief loss of consciousness. Emergency hospitalization costs $28,000. Follow-up neurology evaluation and monitoring cost $7,500. The patient misses three weeks of work ($6,200). A non-economic multiplier of 3 is applied for the severity and terror of a nighttime seizure event.
Gross trial value estimate: $41,700 (economic) plus $125,100 (non-economic at 3x) equals approximately $166,800. If the pump is subject to an FDA Class I recall for the exact defect, liability probability may be strong -- estimated at 80 percent. Risk-adjusted value: approximately $133,400 before attorney fees (typically 33-40 percent on contingency), case costs, and any health plan liens.
Catastrophic outcomes -- brain damage from prolonged hypoglycemia or wrongful death -- can produce claims in the millions because of lifetime care costs, lost earning capacity, and the severity of non-economic damages.
The FDA's MAUDE (Manufacturer and User Facility Device Experience) database is a critical resource. It contains adverse event reports submitted by manufacturers, healthcare facilities, and patients. Searching MAUDE for the specific pump model and defect type can reveal whether the manufacturer received prior reports of the same malfunction -- evidence that can support a failure-to-warn or punitive damages claim.
Evidence preservation is essential in device cases. The pump itself, all accessories, packaging, lot numbers, and any downloaded pump data should be preserved immediately. Many pumps store delivery logs, alarm histories, and error codes that can prove or disprove a malfunction. If the pump is returned to the manufacturer before litigation, critical evidence may be lost.
Product liability statutes of limitations vary by state, typically ranging from one year (Kentucky, Louisiana, Tennessee) to six years (Maine, North Dakota). Many states apply a discovery rule that starts the clock when the plaintiff discovers or reasonably should have discovered the injury and its connection to the device defect. Some states also impose a statute of repose that bars claims filed more than a set number of years after the product was first sold, regardless of when the injury occurred. Because insulin pumps are used continuously and replaced every few years, identifying the exact product sale date and applicable repose period is important.
The most common claim types are over-delivery causing severe hypoglycemia, under-delivery causing diabetic ketoacidosis, software errors that display incorrect dosing, infusion set failures, and battery or alarm failures that prevent timely warnings.
No. An FDA recall shows the agency identified a safety concern, but the plaintiff must still prove that the specific defect caused injury in their individual case. However, recall notices can be powerful evidence of a known defect.
Potentially liable parties include the pump manufacturer, the software developer, the infusion set supplier, the pharmacy or distributor, the prescribing physician if the device was inappropriate for the patient, and the training provider if inadequate instruction contributed to harm.
MAUDE (Manufacturer and User Facility Device Experience) is the FDA database of adverse event reports for medical devices. It contains reports from manufacturers, healthcare facilities, and patients about device malfunctions, injuries, and deaths.
Generally yes. FDA approval (510(k) clearance for most pumps) does not immunize a manufacturer from state product liability claims in most jurisdictions. Federal preemption applies mainly to PMA-approved devices, and most insulin pumps are cleared through the 510(k) pathway.
Recoverable damages typically include emergency medical costs, hospitalization, ongoing treatment changes, lost wages, pain and suffering, and in severe hypoglycemia cases involving brain injury or death, catastrophic or wrongful death damages.
No. SettlementCalculator.xyz is operated by Mustafa Bilgic, a non-attorney individual operator. This page is educational research only and is not legal, tax, or financial advice. Consult a licensed attorney for case-specific guidance.
The statute of limitations varies by state, typically ranging from one to six years for product liability claims. Some states apply a discovery rule that starts the clock when the plaintiff knew or should have known about the injury and its cause. Consult a licensed attorney promptly.